WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and the Children’s Hospital of Fudan University (CHFU), based in Shanghai, have partnered to advance precision medicine in China. It brings WuXi NextCODE’s genomic testing capabilities directly into clinical use for the first time in China, and builds on CHFU’s preeminence in pediatrics to immediately begin delivering benefits to thousands of rare disease patients across China.
WuXi NextCODE is deploying the full range of its renowned genome testing infrastructure for CHFU: CLIA sequencing, massively scalable informatics, and the most powerful interpretation tools and clinical genetics expertise. As a result, CHFU will be able to offer Chinese rare disease patients the same sequence-based diagnostics now available to patients in the U.S. and Europe through partners including Boston Children’s Hospital and Genomics England. CHFU, which sees as many as 7,000 patients every day, can now rapidly scale up sequence-based testing to resolve more undiagnosed cases.